1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd.

IPA
ImmunoPrecise Antibodies Ltd.US flagNASDAQ Global Market
1.62
USD
+0.04
- -
74.77MMarket Cap

Total Valuation

ImmunoPrecise Antibodies Ltd. carries a market capitalization of 74.77M, placing it among publicly traded companies globally. Its enterprise value stands at 53.42M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap74.77M
Enterprise Value53.42M

Share Statistics

ImmunoPrecise Antibodies Ltd. currently has 46.15M shares outstanding.

Shares Outstanding46.15M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 3.66, and the price-to-book ratio stands at 17.98.

PE RatioN/A
PS Ratio3.66
PB Ratio17.98
P/TBV Ratio3.96
P/FCF Ratio-10.29
P/OCF Ratio-9.33

Enterprise Valuation

EV / Sales2.38
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

ImmunoPrecise Antibodies Ltd. maintains a current ratio of 2.17, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 17.95, indicating elevated leverage, while an interest coverage ratio of -24.25 demonstrates limited ability to service its debt obligations.

Current Ratio2.17
Quick Ratio2.10
Debt / Equity17.95
Debt / EBITDA-0.53
Interest Coverage-24.25

Financial Efficiency

Return on Equity (ROE)-262.14
Return on Assets (ROA)-58.36
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover8.11

Taxes

Income Tax-3.35M
Effective Tax RateN/A

Stock Price Statistics

ImmunoPrecise Antibodies Ltd.'s stock has gained approximately 297.05882% over the past 52 weeks. The 50-day moving average sits at 1.94, while the 200-day moving average is 0.84.

Beta (5Y)N/A
52-Week Price Change297.05882%
50-Day Moving Average1.94
200-Day Moving Average0.84
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, ImmunoPrecise Antibodies Ltd. generated 22.42M in revenue and converted that into -29.19M in net income, yielding earnings per share of -0.85. EBITDA reached -7.06M, while operating income came in at -11.72M.

Revenue22.42M
Gross Profit12.72M
Operating Income-11.72M
Pretax Income-33.67M
Net Income-29.19M
EBITDA-7.06M
EBIT-11.72M
Earnings Per Share (EPS)-0.85

Balance Sheet

ImmunoPrecise Antibodies Ltd. holds 32.44M in cash and equivalents against 3.72M in total debt, resulting in a net debt position of -4.90M. Total book value stands at 4.57M, with working capital of 19.56M providing operational flexibility.

Cash & Cash Equivalents32.44M
Total Debt3.72M
Net Debt-4.90M
Equity (Book Value)4.57M
Book Value Per Share0.13
Working Capital19.56M

Cash Flow

ImmunoPrecise Antibodies Ltd. produced -8.80M in operating cash flow over the past twelve months. After subtracting -818,000.00 in capital expenditures, free cash flow totaled -9.62M - equivalent to -0.27 per share.

Operating Cash Flow-8.80M
Capital Expenditures-818,000.00
Free Cash Flow-9.62M
FCF Per Share-0.27

Margins

ImmunoPrecise Antibodies Ltd. operates with a gross margin of 56.74, reflecting its pricing power and cost economics. The operating margin of -52.29 and net profit margin of -130.23 provide insight into operational efficiency.

Gross Margin56.74
Operating Margin-52.29
Pretax Margin-150.21
Profit Margin-130.23
EBITDA Margin-31.48

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-14.40
FCF Yield-9.72

Stock Splits

ImmunoPrecise Antibodies Ltd.'s most recent stock split took place on November 23, 2020 with a 5:1 split ratio.

Last Split Date11/23/2020
Split Ratio5:1

Scores

ImmunoPrecise Antibodies Ltd. posts an Altman Z-Score of -1.89, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-1.89